Integra LifeSciences Holdings Corporation

Total Valuation

Integra LifeSciences Holdings Corporation carries a market capitalization of 1.25B, placing it among publicly traded companies globally. Its enterprise value stands at 2.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Integra LifeSciences Holdings Corporation currently has 77.82M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.44, and the price-to-book ratio stands at 1.74.

Enterprise Valuation

On an enterprise value basis, Integra LifeSciences Holdings Corporation trades at an EV/EBITDA multiple of 12.64 and an EV/FCF ratio of 11.27. The EV/Sales ratio of 1.52 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 55.67 provides insight into valuation relative to core operating earnings.

Financial Position

Integra LifeSciences Holdings Corporation maintains a current ratio of 3.38, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 195.65, indicating elevated leverage, while an interest coverage ratio of 2.20 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Integra LifeSciences Holdings Corporation has paid -40.08M in income taxes, reflecting an effective tax rate of 139.54.

Stock Price Statistics

Integra LifeSciences Holdings Corporation's stock has gained approximately 22.90076% over the past 52 weeks. The 50-day moving average sits at 11.97, while the 200-day moving average is 12.61.

Income Statement

Over the trailing twelve months, Integra LifeSciences Holdings Corporation generated 1.64B in revenue and converted that into -495.80M in net income, yielding earnings per share of -6.40. EBITDA reached 198.04M, while operating income came in at 44.96M.

Balance Sheet

Integra LifeSciences Holdings Corporation holds 265.50M in cash and equivalents against 2.04B in total debt, resulting in a net debt position of 1.63B. Total book value stands at 419.75M, with working capital of 825.17M providing operational flexibility.

Cash Flow

Integra LifeSciences Holdings Corporation produced 71.44M in operating cash flow over the past twelve months. After subtracting -67.36M in capital expenditures, free cash flow totaled 4.08M - equivalent to 0.05 per share.

Margins

Integra LifeSciences Holdings Corporation operates with a gross margin of 51.94, reflecting its pricing power and cost economics. The operating margin of 2.73 and net profit margin of -30.15 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Integra LifeSciences Holdings Corporation's most recent stock split took place on January 4, 2017 with a 1:2 split ratio.

Scores

Integra LifeSciences Holdings Corporation posts an Altman Z-Score of 1.98, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.